# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!


Extrahepatic bile duct cancer

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 31-40 of 46 results.
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Status: Recruiting
Last Changed: Sep 09, 2019
First Received: Feb 20, 2017
Disease(s): Melanoma, Head and Neck Cancer, Lymphoma, Breast Cancer, Pancreatic Cancer, Liver Cancer, Colon Cancer, Lung Cancer, Glioblastoma, Bile Duct Cancer, Ovarian Cancer, Sarcoma, Squamous Cell Carcinoma
Intervention(s): INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
Locations: USC Norris, Los Angeles, California, United States
USC HOAG, Newport Beach, California, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
UMASS Memorial Medical Center, Worcester, Massachusetts, United States
Columbia University Medical Center, New York, New York, United States
... and 3 other locations.
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Status: Recruiting
Last Changed: Aug 21, 2019
First Received: Jul 15, 2016
Disease(s): Advanced Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Hepatic Cancer, Hepatic Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
Intervention(s): H3B-6527
Locations: USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
UC Irvine Medical Center, Orange, California, United States
UCLA Medical Center, Santa Monica, California, United States
Georgetown Unversity Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
... and 39 other locations.
Integrated Cancer Repository for Cancer Research
Status: Recruiting
Last Changed: Sep 04, 2019
First Received: Dec 16, 2013
Disease(s): Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, GIST, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, CNS Tumor, CNS Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia
Locations: Penrose Cancer Center, Colorado Springs, Colorado, United States
Porter Adventist Hospital, Denver, Colorado, United States
St. Anthony Hospital, Lakewood, Colorado, United States
Parker Adventist Hospital, Parker, Colorado, United States
St. Mary Corwin Medical Center, Pueblo, Colorado, United States
... and 71 other locations.
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Status: Recruiting
Last Changed: Apr 22, 2019
First Received: May 01, 2014
Disease(s): Cholangiocarcinoma
Intervention(s): CX-4945, Cisplatin, Gemcitabine
Locations: Mayo Clinic, Scottsdale, Arizona, United States
University of Colorado- Denver, Aurora, Colorado, United States
Mayo Clinic, Jacksonville, Florida, United States
Mayo Clinic, Rochester, Minnesota, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
... and 11 other locations.
A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma
Status: Recruiting
Last Changed: Mar 12, 2019
First Received: Dec 19, 2017
Disease(s): Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Intervention(s): ABC294640
Locations: Mayo Clinic Cancer Center, Phoenix, Arizona, United States
Emory University, Atlanta, Georgia, United States
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
MD Anderson Cancer Center, Houston, Texas, United States
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
... and 1 other locations.
Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)
Status: Available
Last Changed: Nov 29, 2018
First Received: Jan 30, 2018
Disease(s): Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic
Intervention(s): ABC294640
Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma
Status: Recruiting
Last Changed: Sep 20, 2018
First Received: Jul 27, 2018
Disease(s): Cholangiocarcinoma
Intervention(s): mFOLFOXIRI
Locations: Jarin Chindaprasirt, Khon Kaen, Thailand
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Status: Recruiting
Last Changed: Sep 19, 2019
First Received: Jul 26, 2019
Disease(s): Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
Intervention(s): LMB-100, Tofacitinib, Mesothelin Expression
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland, United States
EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice
Status: Recruiting
Last Changed: Jul 24, 2019
First Received: Apr 11, 2018
Disease(s): Pancreatic Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Ampulla of Vater Cancer, Jaundice, Obstructive
Intervention(s): Endoscopic ultrasound
Locations: Gastroenterology Department, Clinical Hospital Colentina, Bucharest, Romania
Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
Status: Available
Last Changed: Sep 13, 2019
First Received: Sep 12, 2019
Disease(s): Intrahepatic Cholangiocarcinoma
Intervention(s): derazantinib